Home / FINANCIAL NEWS / Gabelli Comments on Exactech, Inc.’s FY2018 Earnings (EXAC)

Gabelli Comments on Exactech, Inc.’s FY2018 Earnings (EXAC)

Exactech, Inc. (NASDAQ:EXAC) – Analysts at Gabelli cut their FY2018 earnings per share (EPS) estimates for Exactech in a research note issued on Wednesday. Gabelli analyst J. Tsai now forecasts that the brokerage will earn $1.40 per share for the year, down from their previous forecast of $1.45. Gabelli also issued estimates for Exactech’s FY2019 earnings at $1.60 EPS and FY2020 earnings at $1.75 EPS.

Several other research firms have also weighed in on EXAC. TheStreet lowered Exactech from a “b-” rating to a “c” rating in a research note on Tuesday, February 21st. Zacks Investment Research lowered Exactech from a “hold” rating to a “sell” rating in a research note on Thursday, February 2nd.

Earnings History and Estimates for Exactech (NASDAQ:EXAC)

“Gabelli Comments on Exactech, Inc.’s FY2018 Earnings (EXAC)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was stolen and republished in violation of US & international trademark and copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/02/26/gabelli-comments-on-exactech-inc-s-fy2018-earnings-exac.html.

Shares of Exactech (NASDAQ:EXAC) opened at 24.60 on Friday. The company has a 50-day moving average price of $25.73 and a 200 day moving average price of $26.64. Exactech has a 12-month low of $18.14 and a 12-month high of $29.00. The firm has a market capitalization of $349.25 million, a price-to-earnings ratio of 2460.00 and a beta of 0.84.

Exactech (NASDAQ:EXAC) last posted its earnings results on Tuesday, February 21st. The company reported $0.34 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.02. Exactech had a return on equity of 6.81% and a net margin of 6.34%. The firm earned $66.20 million during the quarter, compared to analyst estimates of $66 million. During the same period in the previous year, the company earned $0.29 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis.

A number of institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Exactech by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 751,750 shares of the company’s stock valued at $20,523,000 after buying an additional 29,515 shares during the last quarter. State Street Corp raised its position in Exactech by 11.3% in the fourth quarter. State Street Corp now owns 245,639 shares of the company’s stock valued at $6,707,000 after buying an additional 25,011 shares during the last quarter. Royce & Associates LP raised its position in Exactech by 6.1% in the fourth quarter. Royce & Associates LP now owns 240,128 shares of the company’s stock valued at $6,555,000 after buying an additional 13,700 shares during the last quarter. Renaissance Technologies LLC raised its position in Exactech by 7.2% in the fourth quarter. Renaissance Technologies LLC now owns 105,700 shares of the company’s stock valued at $2,886,000 after buying an additional 7,100 shares during the last quarter. Finally, Allianz Asset Management AG raised its position in Exactech by 53.4% in the fourth quarter. Allianz Asset Management AG now owns 97,220 shares of the company’s stock valued at $2,654,000 after buying an additional 33,830 shares during the last quarter. 64.24% of the stock is currently owned by hedge funds and other institutional investors.

“Gabelli Comments on Exactech, Inc.’s FY2018 Earnings (EXAC)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was stolen and republished in violation of US & international trademark and copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/02/26/gabelli-comments-on-exactech-inc-s-fy2018-earnings-exac.html.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines.

5 Day Chart for NASDAQ:EXAC

What are top analysts saying about Exactech Inc.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Exactech Inc. and related companies.

Check Also

NewStar Financial (NEWS) EPS Estimated At $0.13; Country Trust Bank Lifted Halliburton Company Common (HAL) Position

October 1, 2017 – By Ellis Scott Country …

Leave a Reply

Your email address will not be published. Required fields are marked *

five × one =